Section 27 of the Drugs and Cosmetics Act prescribes penalties for manufacturing or selling adulterated, spurious, or misbranded drugs. Mace Corporate Associates offers expert legal guidance on compliance and litigation related to this section, ensuring pharmaceutical businesses operate within regulatory frameworks while minimizing legal risks and protecting public health standards.